Status of tumor markers in epithelial ovarian cancer has there been any progress? A review

Gynecologic Oncology

Volumn 120, Issue 1, 2011, Pages 152-157

  Husseinzadeh, Nader ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Epithelial ovarian cancer; Screening ovarian tumor markers

Indexed keywords

ACUTE PHASE PROTEIN; CA 125 ANTIGEN; CYTOKINE; GLYCOPROTEIN; LIVER PROTEIN; SERINE PROTEINASE; TUMOR MARKER;

CANCER DIAGNOSIS; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENOMICS; OVARY CANCER; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY;

FEMALE; GENOMICS; HUMANS; OVARIAN NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649906756     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.09.002     Document Type: Review

References (63)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics CA: Cancer J Clin 59 4 2009 225 229
2. Kosary CL. SEER survival monograph, NCI 2008:133-142(seer.cancer.gov).
3. J. Engel, R. Eckel, G. Schubert-Fritschle, J. Kerr, W. Kuhn, and J. Diebolt Moderate progress for ovarian cancer in last 20 years: prolongation of survival; but no improvement in the cure rate Eur J Cancer 38 2002 2435 2445
4. R.C. Bast Jr. Status of tumor markers in ovarian cancer screening J Clin Oncol 21 2003 200s 205s
5. National Institute of Health consensus conference Ovarian Cancer Screening, treatment and follow-up. NIH Consensus Development Panel on Ovarian Cancer JAMA 274 1995 491 497
6. E.F. Petrocoin, A.M. Ardekani, B.A. Hitt, P.J. Levine, V.A. Fusaro, and S.M. Steinberg Use of proteomic patterns in serum to identify ovarian cancer Lancet 359 2002 572 577
7. L. Wagner A test before its time? FDA stalls distribution process of proteomic test J Natl Cancer Inst 96 2004 500 501
8. E. Diamandis Analysis of serum proteomic patterns for early cancer diagnosis; drawing attention to potential problems J Natl Cancer Inst 96 2004 353 356
9. L.A. Liotta, M. Lowenthal, A. Mehta, T.P. Contrads, T.D. Veenstra, and D.A. Fishman Importance of communication between producers and consumers of publically available experimental data J Natl Cancer Inst 97 2005 310 314
10. M.R. Anderson, B.A. Goff, K.A. Lowe, N. Scholler, L. Bergen, and C.W. Dresher Combining a symptom index with CA125 to improve detection rate of ovarian cancer Cancer 113 2008 484 489
11. M.R. Anderson, B.A. Goff, K.A. Lowe, N. Scholler, L. Bergen, and C.W. Dresher Use of a symptom index CA-125,and HE$ to predict ovarian cancer Gynecol Oncol 116 2010 378 383
12. R.G. Moore, M. Jabre-Raughley, A.K. Brown, K.M. Robinson, C.M. Miller, and J.W. Allard Comparison of a novel multiple marker assay versus the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass Gynecol Oncol 112 45 2009 S25 S26 Abstract
13. J.D. Anderson, K.L. Boylan, F.S. Xue, L.B. Anderson, T.W. Markowski, and L. Higgins Identification of candied biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis Electrophoresis 31 2010 599 610
14. G.L. Anderson, M. McIntosh, W.U. Lieling, M. Barnett, G. Goodman, and J.D. Thorpe Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study J Natl Cancer Inst 102 2010 26 38
15. R.C. Bast, D. Badgwell, A. Lu, R. Marquez, D. Rosrn, and J. Liu New Tumor Markers: Ca 125 and beyond Int J Gyncol cancer 15 2005 274 281
16. M. Keichle, A. Jacobsen, U. Schwartz-Boeger, J. Hedderich, J. Pfisterer, and N. Arnold Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade and differentiation Cancer 91 2001 534 540
17. J. Hu, V. Khanna, M.W. Jones, and U. Sutri Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with potential application for prognosis Gynecol Oncol 89 2003 369 375
18. V. Shridhar, J. Lee, A. Pandita, S. Iturria, R. Avula, and J. Stub Genetic analysis of early- versus late ovarian tumors Cancer Res 61 2001 5895 5904
19. K.L. Terry, P.M. Sluss, S.J. Skates, S.C. Mok, B. Yeh, and A.F. Vitivis Blood and urine markers for ovarian cancer: a comprehensive review Dis Marker 20 2004 53 70
20. K.J. Helzlsouer, T.L. Bush, A.J. Alberg, K.M. Bass, H. Zacur, and G.W. Comstock Prospective study of serumCA-125 levels as markers of ovarian cancer JAMA 269 1993 1123 1126
21. N. Einhorn, K. Sjovall, R.C. Knapp, P. Hall, R.E. Scully, and R.C. Bast Prospective evaluation of serum CA125 levels for early detection of ovarian cancer Obstet Gynecol 80 1992 14 18
22. R.C. Bast, N. Urban, V. Shridhar, D. Smith, Z. Zhang, and S. Skates Early detection of ovarian cancer: promise and reality Cancer Treat Res 107 2002 61 97
23. F.J. Xu, Y.H. Yu, B.Y. Li, M. Moradi, S. Elg, and C. Lane Development of two new monoclonal antibodies reactive to surface antigen present on human ovarian epithelial cancer cell lines Cancer Res 51 1991 4012 4019
24. C. VanHaaflen-day, Y. Shen, F. XU, Y. Yu, A. Burchuck, L. Havrilesky, H.W.A. deBruijn, A.G.J. Van der Zee, R.C. Bast, and N. Hacker OXV1, macrophage stimulating factor and CA-125 II as tumor marker for epithelial ovarian carcinoma. A critical appraisal Cancer 92 2001 2837 2844
25. Z. Zhang, Y. YU, F. XU, A. Burchuck, C. VanHaaflen-day, and L.J. Havrilesky Combining multiple serum markers improves detection of stage I epithelial ovarian cancer Gynecol Oncol 107 2007 526 531
26. I. Hellstrom, J. Raycraft, M. Hayden-Ledbetter, J.A. Ledbetter, M. Schummer, and M. McIntosh The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res 63 2003 3695 3700
27. A. Brown, C. Miller, K. Robinson, E. Somers, J. Allard, and C.O. Granai Differential expression of CA125 and a novel marker HE4 in epithelial ovarian cancer J Clin Oncol 26 s 2008 Abstract #5533
28. R. Drapkin, H.H. Von Horsten, Y. Lin, S.C. Mok, C.P. Crum, and W.R. Welsh Human epididymis protein 4 (HE4) is a secreted glycoprotein that is over expressed by serous and endometriod carcinoma Cancer Res 66 2005 2162 2169
29. K. Huhtinen, P. Suvite, J. Hiissa, J. Junnila, J. Huvila, and H. Kujari Serum HE4 concentration differentiates malignant ovatumours from ovarian endometriotic cysts Brit J Cancer 2009 100 1319 1315
30. R.G. Moore, A.K. Brown, M.C. Miller, S. Skates, W.J. Allard, and T. Verch The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol Oncol 108 2008 402 408
31. R.G. Moore, D.S. McMeekin, A.K. Brown, P. DiSilvestro, M.C. Miller, and W.J. Allard A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol Oncol 112 2009 40 46
32. M.W. Mcintosh, C. Drescher, B. Karlan, N. Scholler, N. Urban, and K.E. Hellstrom Combining CA125 and SMR serum markers for diagnosis and detection of ovarian carcinoma Gynecol Oncol 96 2004 9 15
33. D. Badgwell, Z. Lu, L. Cole, H. Fritsche, E.N. Atkinson, and E. Somers Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary HCG free beta subunit and urinary hCG beta core fragment Gynecology 106 2007 490 497
34. B. Ye, D.W. Cramer, S.J. Skates, S.P. Gygi, V. Pratomo, and L. Fu Haptoglobin-α subunit as potential biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry Clin Cancer Res 9 2003 2904 2911
35. H. Matsuzaki, H. Kobayash, T. Yagyu, K. Wakahara, T. Kondo, and N. Kurita Plasma bikunin as a favorable prognostic factor in ovarian cancer J Clin Oncol 23 2005 1463 1472
36. L. Marnell, C. Mold, and T.W. Du Clos C-reactive protein: ligands, receptors and role in inflammation Clin Immunol 117 2005 104 111
37. K. Hefler-Frischmuth, L.A. Hefler, G. Heinze, V. Paseka, and C. Grimm Temper CB Serum. C-reactive protein in the differential diagnosis of ovarian masses Euro J Obstet Gynecol Reprod Biol 147 2009 65 68
38. S.D. Deodhar C-reactive protein: the best laboratory indicator available for monitoring disease activity Cleve Clin J Med 56 2 1989 126 130
39. J. Kodama, Y. Miyagi, and N. Seki Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer Eur J Obstet Gynecol Reprod Biol 82 1999 107 110
40. L. Hefler, N. Concin, and G. Hofstetter Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer Clin Can Res 14 3 2008 710 714
41. D. Roberts, S.J. Williams, D. Cvetkovic, J.K. Weinstein, A.K. Godwin, and S.W. Johnson Decreased expression of retinol-binding protein associated with malignant transformation of the ovarian surface epithelium DNA Cell Biol 21 2002 11 19
42. G. Mor, I. Visintin, Y. Lai, H. Zhao, T. Rutherford, and L. Yue Serum protein markers for early detection of ovarian cancer Proc Nat Acad Sci 102 2005 7677 7682
43. L.E. Moore, E.T. Fung, M. McGuire, C.C. Rabkin, A. Molinaro, and Z. Wang Evaluation of Apolipoprotein A1 and posttranslationally modified forms of Transthyretin as a biomarkers for ovarian cancer early detection in an independent study population Cancer Epidemiol Biomark Prev 15 2006 1641-1466
44. Z. Zhang, R.C. Bast, Y. YU, J. Li, L.J. Sokol, and A.I. Rai Three biomarkers identified from serum proteomic analysis for detection of early stage ovarian cancer Cancer Res 64 2004 5882 5890
45. K.R. Kozak, F. Su, J.P. White legge, K. Faull, S. Reddy, and R. Farias-Eisner Characterization of serum biomarkers for detection of early stage ovarian cancer Proteomics 5 2005 4589 4596
46. I. Visintin, Z. Feng, G. Longton, D.C. Ward, A.B. Alvero, and Y. Lai Clin Cancer Res 14 2008 1065 1072
47. V. Nossov, F. Su, M. Amneus, M. Birrer, T. Robins, and J. Kotlerman Validation of serum biomarkers for detection of early stage ovarian cancer Am J Obstet Gynecol 200 2009 639.e1-5
48. J.D. Gordon, S. Mesiano, C.J. Zaloudek, and R.B. Jaffe Vascular endothelial growth factor localization in human ovary and fallopian tube: possible role in reproductive function and ovarian cyst formation J Clin Endocrinol Metab 81 1996 353 369
49. L.A. Hefler, R. Zollinger, C. Grimm, A.K. Sood, W.F. Cheng, and A. Gadducci A Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer Gynecol Oncol 103 2006 512 517
50. C. Rudlowski, A.K. Pickart, C. Fuhljahn, T. Friepoertner, B. Schlehe, and S. Biesterfeld Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long term follow-up Int J Gynecol Cancer 16 2006 183 189
51. B.C. Cooper, J.M. Ritchie, C.L.W. Broghammer, J. Coffin, J.I. Sorosky, and R.E. Buller Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer Clin Cancer Res 8 2002 3103 3319
52. M. Suzki, M. Ohwada, Y. Tamada, T. Hanamura, and M. Nagatomo Macrophage colony stimulating factor as a tumor marker for epithelial ovarian cancer Obstet Gynecol 82 1993 946 950
53. J.H. Kim, S.J. Skates, U. Toshimitsu, K.K. Wong, J.O. Schorge, and C.M. Feltmate Osteopontin as a potential diagnostic biomarker in ovarian cancer JAMA 287 2002 1671 1679
54. K.A. Brakora, H. Lee, R. Yusuf, L. Sullivan, A. Harris, and T. Colleta Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer Gynecol Oncol 93 2004 361 365 (Pubitemid 38507602)
55. L.O. Schorge, R.D. Drake, H. Lee, S.J. Skates, R. Rajanbabu, and D.S. Miller Osteopontin as a adjunct to CA-125 in detecting recurrent ovarian cancer Clin Cancer Res 10 2004 3473 3478
56. K.A. Furger, R.K. Menon, A.B. Tuckl, V.H. Bramwell, and A.F. Chambers The functional and clinical roles of osteopontin in cancer and metastasis Curr Mol Med 1 2001 621 632
57. E.P. Diamandis, and G.M. Yousef Human tissue Kallikreins: a family of new cancer biomarkers Clin Chem 48 2002 1198 1205
58. G.M. Yousef, M.E. Polymeris, G.M. Yacoub, Scorilas, A. Soosaipillai, and C. Popalis Parallel over expression of seven Kallikrein genes in ovarian Cancer. Cancer Res 63 2003 2223 2227
59. D.G. Rosen, l. Wang, J.N. Atkins, Y. Yu, K.H. Lu, and E.P. Diamandis Potential markers that complement expression epithelial ovarian cancer Gynecol Oncol 99 2005 267 277
60. L.Y. Luo, D. Katsaros, A. Scorilas, S. Fracchioli, R. Piccinno, and I.A. Rigault de la Longrias Prognostic value of human kallikrein10 expression in epithelial ovarian carcinoma Clin Cancer Res 7 2001 2372 2379
61. T. Kishi, L. Grass, A. Soosaipillai, A. Scoralis, N. Harbeck, and B. Schmalfeld Human Kallikreins 8, a novel biomarker for ovarian carcinoma Cancer Res 63 2003 2771 2774
62. M.W. McIntosh, Y. Liu, C. Drescher, N. Urban, and E. Diamandis Validation and characterization of human Kallikrein 11 as a serum tumor marker for diagnosis of ovarian cancer Clin Cancer Res 13 2007 4422 4428
63. S.C. Mok, J. Chao, S. Skates, K.K. Wong, G.K. Yiu, and M.G. Muto Prostasin, a potential serum tumor marker for ovarian cancer: identification through microarray technology J Natl Cancer Inst 3 2001 93(19):1458-1464